Across TCGA pan-cancer cohorts, LIPJ Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LIPJ data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LIPJ Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LIPJ expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC and UCEC are the cancer types where LIPJ Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.080	0.743	<.001	12	view →
UCEC	DFS	Median	III,IV	1.000	0.542	.047	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: LIPJ tumor-vs-normal RNA expression · all LIPJ data types